Tezepelumab, a monoclonal antibody targeting TSLP, received approval in 2021 for the treatment of asthma, chronic obstructive pulmonary disease (COPD), and CRSwNP (130). The gene discussed is TSLP; the disease is chronic obstructive pulmonary disease.